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severe aortoiliac occlusive disease. This claim is supported
by comparison of the mean total hospital cost ($10,585
for graft versus $9,161 for stent per limb affected). First, as
one of the experts in the discussion panel noted, the cost
of surgery is probably underestimated. Second, the
authors reported cost per limb affected rather than per
patient treated. Eighty-seven percent of the patients in the
surgery group and only 15% of the patients in the stent
group who underwent treatment had bilateral disease.
This nonrandomized assignment of patients with bilateral
disease favoring surgery adversely impacts on the cost for
the stent group. If more patients with bilateral disease had
stent deployment rather than surgery, the cost for the
stent group would be markedly reduced. By the current
assignment of most patients with bilateral disease to the
surgery group, the authors essentially reduced the cost of
surgery by 50%. It would be important to know the num-
ber of stents used per case because this information would
have an impact on the cost. For example, instead of using
two stents to treat a long lesion, one long stent would
lower the cost of the procedure.
Furthermore, I disagree with the statement that the
cost of the operating room time and the longer hospital-
ization (10 days for surgery versus 2 days for stenting) for
the surgery group did not impact on the total hospital
cost. The authors failed to include in the cost of surgery
the anesthesiologist's fees, the consultant's fees (to man-
age the severe complications in the surgery group), and
the costs associated with the preoperative workup and
evaluation before surgery, which are not required for stent
deployment.
Interventional radiologists at my institution place
stents for severe aortoiliac disease on an outpatient/ambu-
latory basis. Patients arrive in the morning for their stent
procedure and normally leave the hospital by late after-
noon on the same day. Rarely do these patients stay
overnight, unless a complication, which is rare, has
occurred. In this case, they are admitted overnight for
observation. The length of hospitalization for the stent
group in the article is higher than in my institution. In
summary, the reader should be made aware of the inher-
ent flaws in this article. A randomized, prospective study
should be undertaken before conclusions, which impact
on the decision of surgery versus stent deployment for the
treatment of severe aortoiliac disease, can be made.
Wen Y. Wang, MD
Vascular and Interventional Radiology Section
Department of Radiology
St. Luke's-Roosevelt Hospital Center
New York, NY
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Reply
We appreciate the opportunity to respond to Dr
Wang's comments concerning our manuscript.! He con-
tends that there are significant flaws in our data presenta-
tion and raises some issues that require rebuttal, even
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though they were clearly stated in the manuscript. We can
assure Dr Wang that our data are truly representative of a
carefully studied group of patients with severe aortoiliac
occlusive disease, and we offer the following point-by-
point responses.
1. Our expert interventional radiology colleagues
were not included in the author list because they
did not assist in writing the manuscript nor were
they involved with the data collection for the pri-
mary study focus, which was cost. Previous publi-
cations from our institution concerning other
aspects of aortoiliac occlusive disease clearly give
deserved credit to these skilled individuals.2-4
Editors have taught us all to be increasingly cau-
tious in listing coauthors.
2. All the patients in this series were potential candi-
dates for operative intervention. This is in contrast
to other studies that have compared angioplasty
candidates with surgical patients.5,6 Our patients
with more severe disease allow the comparison of
the two therapies where they are currently compet-
ing with each other. In our practice, the treatment
for a category I iliac artery lesion is angioplasty with
or without stent deployment. Therefore, as was
clearly stated in the manuscript, these are nonsurgi-
cal cases. They could not be included when only
disease categories II to IV were studied. Also, as dis-
played in the manuscript, there was no selection
bias (any significant difference) between the two
groups.
3. Regarding a potential patency bias as a result of
group differences in infrainguinal occlusive disease,
this factor was not significant according to univari-
ate analysis. Therefore, Dr Wang's gross estimate
without statistical considerations is in error.
4. To answer another question, one stent was
deployed in 45 cases (57%), 2 in 25 cases (31.6%),
3 in 7 cases (8.9%), and 4 in 2 cases (2.5%).
5. The matter of cost analysis is more complex, con-
sisting of a number of items. First is the inclusion
of the anesthesia. Professional medicare reimburse-
ment for a 3-hour aortobifemoral (or aortobi-iliac)
bypass grafting procedure surprisingly did not
result in a statistically significant increase in mean
total cost of surgery ($10,830 versus $9161, P =
.172) and would not have changed our basic con-
clusions. However, we agree that tabulation of all
costs is more appropriate. We also would have liked
to include the cost of secondary procedures, but
unfortunately including the cost of failed proce-
dures (there were more stem failures) would have
been too complicated. We originally tried to
include preoperative costs, but this too was com-
plex because some patients referred to the clinic
had excellent arteriograms in hand and others had
to have better images before a treatment could be
selected. We were as surprised as Dr Wang was that
operating room time and length of stay data did
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not influence the cost to the extent anticipated, or
even significantly. We agree with Dr Wang that
stents can be deployed safely on an outpatient
basis, and this is our current practice. We did not
begin our program with that premise, however. On
the other hand, the length of stay for direct surgi-
cal reconstruction has decreased significanfiy dur-
ing the last few years. Therefore, these cost data do
not fully reflect the ongoing efforts to streamline
both procedures. Although we admit that the cost
data published in this manuscript are not perfect,
they are our best attempt at presenting the data
with appropriate cohort comparisons.
6. These cost data were obtained directly from thc
accounting office on the basis of accurate patient
admission statistics and were not underestimated.
They are accurate. The discussant to whom Dr
Wang refers was speculating and was not an
informed panel expert.
7. As admitted in the manuscript, the cost per patient
encounter was higher for surgical reconstruction as
compared with angioplasty with or without stenting.
However, we believe that the cost estimates derived
on a per-limb-treated basis are the best method of
comparison and provide a perspective not common-
ly offered in the interventional radiology literature.
That is to say, on the basis of these data, direct sur-
gical reconstruction offered better value per limb
treated in terms of clinical improvement and long-
term patency rates. Although Dr Wang and other
interventional radiologists might contend that this
endpoint is unfair because angioplasty was done
more for unilateral disease and bypass grafting was
done more for bilateral disease, the per procedure or
per patient perspective found in much of the radiol-
ogy literature is unfair in the other direction.
8. It is well recognized that procedural and physician
charges for angioplasty and stenting are rising as a
result of more sophisticated imaging and instru-
mentation and that those for surgical bypass graft-
ing are falling because of drastic reimbursement
trends. The results of the prospective, randomized
trial that Dr Wang suggests, if it includes cost of
reintervention and is performed on those patients
with more extensive aortoiliac disease than normal-
ly treated with angioplasty, might surprise him and
his colleagues. We too would welcome it, but until
such a trial shows otherwise, we believe that our
data reflect a true picture of comparative costs for
these procedures when applied to patients with
severe forms of aortoiliac occlusive disease.
Jeffrey L. Ballard, MD
Associate Professor of Surgery
Division ofVascular Surgery
Lorna Linda University Medical Center
Lorna Linda, Calif
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Regarding "Detection of active cytomegalovirus
infection in inflammatory aortic aneurysms with
RNA polymerase chain reaction"
To the Editors
In addition to Dr Tanaka's reply (J Vasc Surg
1998:27:587-8), we would like to provide some addition-
al comments to the critique by Dr Satta and colleagues l
regarding possible cytomegalovirus pathogenesis in
human aortic diseases. We want to avoid misunderstand-
ing because it is slightly complex.
First, we should emphasize that we suggested
cytomegalovirus as a possible pathogen of so-called
inflammatory abdominal aortic aneurysms (IAAAs)2 but
not of conventional atherosclerotic abdominal aortic
aneurysms (AAAs).3,4 Cytomegalovirus transcripts could
be detected only in IAAAs but not in AAAB. Thus, we
concluded that cytomegalovirus transcripts might play a
role in the sustained chronic inflammatory reaction and
massive adventitial fibrosis of IAAAs but did not clearly
suggest the pathologic nature of AAAB.
Second, I am afraid that the authors might have con-
fused the status of cytomegalovirus infection in such aortic
diseases because the analytical technique that they used does
not seem to be appropriate for this purpose. The process of
infection ofhuman Herpesviridae is not fully elucidated, but
numerous studies suggest that at least four types of condi-
tions seem to exist in cytomegalovirus infection (Table I).
The following conditions are suggested: type 1, lytic infec-
tion associated with cytomegalic inclusion body that leads
to the death ofthe host cell; type 2, persistent infection with
virus production that does not lead to cell death; type 3,
latent infection that expresses some viral genes without viral
production; and type 4, postinfection with viral genome and
without viral gene expression. Clearly, type 1 infection can
